Page last updated: 2024-11-04

clenbuterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2783
CHEMBL ID49080
CHEBI ID174690
SCHEMBL ID4722
MeSH IDM0004556

Synonyms (105)

Synonym
(+-)-clenbuterol
chebi:174690 ,
clenbuterolum
1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol
BRD-A75726477-003-04-9
KBIO1_000794
DIVK1C_000794
37148-27-9
1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]ethanol
einecs 256-529-4
nab 365
SPECTRUM_001564
BSPBIO_000409
planipart
einecs 253-366-0
benzyl alcohol, 4-amino-alpha-((tert-butylamino)methyl)-3,5-dichloro-
benzenemethanol, 4-amino-3,5-dichloro-alpha-(((1,1-dimethylethyl)amino)methyl)-
clenbuterolum [inn-latin]
brn 1076467
IDI1_000794
clenbuterol (inn)
contraspasmin (tn)
D07713
planipart [veterinary] (tn)
SPECTRUM5_001497
BSPBIO_002609
PRESTWICK2_000345
BPBIO1_000451
AB00053680
clenbuterol
DB01407
NCGC00163150-02
1-(4-amino-3,5-dichloro-phenyl)-2-tert-butylamino-ethanol
4-amino-3,5-dichloro-alpha-(((1,1-dimethylethyl)amino)methyl)benzenemethanol
4-amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol
(+/-)-clenbuterol
NCGC00163150-01
KBIOGR_001066
KBIOGR_001518
KBIO3_001829
KBIO2_004612
KBIO2_007180
KBIOSS_002044
KBIO2_002044
SPECTRUM3_000975
SPECTRUM4_001099
SPBIO_002330
NINDS_000794
PRESTWICK1_000345
PRESTWICK0_000345
SPECTRUM4_000743
PRESTWICK3_000345
NCGC00163150-03
NCGC00163150-04
bdbm27958
1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethan-1-ol
AC-10284
HMS2089I15
nsc-758633
CHEMBL49080
contraspasmin
FT-0665081
FT-0665080
NCGC00163150-05
AKOS007930151
dtxsid7022833 ,
tox21_112016
cas-37148-27-9
dtxcid902833
xtz6axu7kn ,
nsc 758633
clenbuterol [inn:ban]
dl-clenbuterol
unii-xtz6axu7kn
(rs)-clenbutero
monores
p 5369
clenbuterol [mi]
clenbuterol [inn]
clenbuterol [who-dd]
SCHEMBL4722
NCGC00163150-07
tox21_112016_1
AB00053680-12
4-amino-alpha-[(tert-butylamino)methyl]-3,5-dichlorobenzyl alcohol
4-amino-.alpha.-[(tert-butylamino)methyl]-3,5-dichlorobenzyl alcohol
benzenemethanol, 4-amino-3,5-dichloro-.alpha.-[[(1,1-dimethylethyl)amino]methyl]-
4-amino-3,5-dichloro-.alpha.-(((1,1-dimethylethyl)amino)methyl)benzenemethanol
1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol #
AB00053680_13
benzenemethanol,4-amino-3,5-dichloro-a-[[(1,1-dimethylethyl)amino]methyl]-,(as)-
SR-01000721909-2
SBI-0051858.P002
Q223412
(+/-)-clenbuterol 100 microg/ml in acetonitrile
4-amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcoho
see: c569998
clenbuterol -discontinued
gtpl12582
EN300-25300193
r03cc13
clenbuterolum (inn-latin)
planipart (veterinary)
clenbuterolo
r03ac14

Research Excerpts

Overview

Clenbuterol (CLEN) is a sympathomimetic amine used as a decongestant and bronchodilator. It is not Food and Drug Administration-approved for use in the United States, but may be obtained without a prescription from various unregulated sellers.

ExcerptReferenceRelevance
"Clenbuterol is a banned substance due to the risk of toxicity; however, it is still being used in unknown dose levels in many farm species."( Precision-cut liver slices as a model for assess hepatic cellular response of chitosan-glutathione nanoparticles on cultures treated with zilpaterol and clenbuterol.
Diaz-Torres, R; Dolores-Hernández, M; López Barrera, LD; López-Arellano, R; Piña-Olmos, S; Ramírez-Bribiesca, JE; Ramírez-Noguera, P, 2022
)
1.64
"Clenbuterol is a potent beta-2 agonist widely misused by professional athletes and bodybuilders. "( Adverse events of clenbuterol among athletes: a systematic review of case reports and case series.
Kumari, S; Pal, B; Prabhakar, PK; Sahu, SK; Tewari, D, 2023
)
2.69
"Clenbuterol (CLEN) is a sympathomimetic amine used as a decongestant and bronchodilator while treating breathing disorders. "( A novel murine antibody and an open sandwich immunoassay for the detection of clenbuterol.
Bai, J; Cong, Y; Dong, H; Dong, J; Gao, Z; Huang, JX; Ueda, H; Wei, X; Wu, J; Zhang, L, 2019
)
2.18
"Clenbuterol is a long-acting β-adrenergic agonist that is not Food and Drug Administration-approved for use in the United States, but may be obtained without a prescription from various unregulated sellers. "( Toxicity From Unintentional Pediatric Ingestion of a Performance-Enhancing Drug: A Case Report With Review of Clenbuterol Toxicity and Treatment.
Bonney, CF; Hatten, B; Wang, GS, 2019
)
2.17
"Clenbuterol is a beta"( Beta
Bangsbo, J; Eibye, K; Hostrup, M; Jacobson, GA; Jessen, S; Nordsborg, NB; Solheim, SA, 2020
)
2
"Clenbuterol is a β2 agonist that causes electrolyte disturbances (hypokalemia and hyperglycemia mostly) and death have been described through coronary vasospasm."( Death of an apprentice bodybuilder following 2,4-dinitrophenol and clenbuterol intake.
Barbet, JP; Dufayet, L; Gorgiard, C; Hoizey, G; Ludes, B; Vayssette, F, 2020
)
1.52
"Clenbuterol is a steroid-type drug used in respiratory treatments in both humans and animals. "( Survey of clenbuterol in bovine muscle and liver in Ecuador.
Andrade, P; Betancourt, R; Bravo, J; Enríquez, D; Espinoza, W; Garrido, P; Gualpa, F; Guijarro, M; Medina, L; Montalvo García, G; Moreno, C; Ortega, F; Ramos, L; Stolker, L; Ulic, S; Vaca, I; Vargas Jentzsch, P, 2020
)
2.4
"Clenbuterol is an oral β2-agonist with anabolic and lipolytic effects that is misused as a performance and image enhancing drug."( Clenbuterol: a new toxic substance in paediatrics.
Logan, S; McKie, A; Pollock, L; Tester, AA, 2020
)
2.72
"Clenbuterol is a brain penetrant β"( The β
Boyle, N; Connor, T; Griffin, ÉW; Harkin, A; Harper, P; O'Neill, E; Ryan, KJ; Yssel, JD, 2018
)
1.92
"Clenbuterol (CLB) is an antibiotic and illegal growth promoter drug that has a long half-life and easily remains as residue and contaminates the animal-based food product that leads to various health problems. "( Development of Highly Sensitive Immunosensor for Clenbuterol Detection by Using Poly(3,4-ethylenedioxythiophene)/Graphene Oxide Modified Screen-Printed Carbon Electrode.
Salam, F; Sulaiman, Y; Talib, NAA, 2018
)
2.18
"Clenbuterol hydrochloride is a selective beta-2 adrenergic agonist with uses in both humans and animals. "( Chomping at the Bit: A Descriptive Report on Pediatric Clenbuterol Ingestion.
Akpunonu, P; Baum, RA; Mancuso, N; Rutter, PW; Woolum, J, 2020
)
2.25
"Clenbuterol hydrochloride is a beta-agonist with high potency, extended half-life, and bioavailability of 70% to 80%. "( Chomping at the Bit: A Descriptive Report on Pediatric Clenbuterol Ingestion.
Akpunonu, P; Baum, RA; Mancuso, N; Rutter, PW; Woolum, J, 2020
)
2.25
"Clenbuterol is a member of β2 adrenergic agonists, which is widely used not only as a food additive for livestocks, but also a kind of stimulant for athletes; however, the abuse of clenbuterol may pose a significant negative impact on human health. "( An electrochemical biosensor for clenbuterol detection and pharmacokinetics investigation.
Bo, B; Jiang, B; Li, G; Lou, Y; Miao, P; Pei, D; Shu, Y; Zhu, X, 2013
)
2.11
"Clenbuterol is a β2-agonist approved in the United States for veterinary use in nonfood animals. "( A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding.
Borys, DJ; James, KJ; Scholzen, S; Spiller, HA, 2013
)
2.1
"Clenbuterol is a long-acting β2-adrenoceptor agonist and bronchodilator that is used for the treatment of asthma, but the desired activities reside almost exclusively in the (-)-R-enantiomer. "( Enantioselective disposition of clenbuterol in rats.
Asahi, M; Hirao, T; Hirosawa, I; Ishikawa, M; Ito, H; Kotaki, H; Miyamoto, K; Ogino, M; Sai, Y; Yamada, H, 2014
)
2.13
"Clenbuterol is a well-established β2-agonist, which is prohibited in sports and strictly regulated for use in the livestock industry. "( Statistical significance of hair analysis of clenbuterol to discriminate therapeutic use from contamination.
Anielski, P; Dvorak, J; Geyer, H; Gfrerer, L; Graw, M; Krumbholz, A; Schänzer, W; Thieme, D,
)
1.83
"Clenbuterol is a β2 -adrenergic receptor agonist known to induce skeletal muscle hypertrophy and a slow-to-fast phenotypic shift. "( Chronic clenbuterol treatment compromises force production without directly altering skeletal muscle contractile machinery.
Bonnieu, A; Candau, RB; Cazorla, O; Chopard, A; Douillard, A; Galbès, O; Lacampagne, A; Lionne, C; Philippe, AG; Py, G; Ramonatxo, C; Sanchez, AM; Sirvent, P, 2015
)
2.29
"Clenbuterol is a bronchodilator approved for veterinary use, which in high doses can increase protein deposition and lipolysis similarly to anabolic steroids, and is thereby abused for bodybuilding and weight loss effects."( Rhabdomyolysis Secondary to Clenbuterol Use and Exercise.
Bursua, A; Gimbar, RP; Grimmer, NM; Patel, M, 2016
)
1.45
"Clenbuterol (CLB) is a beta2-adrenergic agonist commonly used in asthma therapy, but is also a non-steroidal anabolic drug often abused in sport doping practices. "( β2-Agonist clenbuterol hinders human monocyte differentiation into dendritic cells.
Cuzziol, N; Del Pinto, T; Giordani, L; Maccari, S; Massimi, A; Pietraforte, D; Sanchez, M; Viora, M, 2015
)
2.25
"Clenbuterol is a β-adrenergic agonist used as additive to increase the muscle mass of meat-producing animals. "( Metabolomic investigation of porcine muscle and fatty tissue after Clenbuterol treatment using gas chromatography/mass spectrometry.
Fu, Y; Han, X; Li, C; Li, G; Li, X, 2016
)
2.11
"Clenbuterol is a β2-adrenergic agonist with veterinary uses that has not been approved by the U.S."( A Case Series of Clenbuterol Toxicity Caused by Adulterated Heroin.
Cumpston, KL; Emswiler, MP; Hieger, MA; Maskell, KF; Miller, KB; Sentz, JT; Wills, BK; Wolf, CE, 2016
)
1.5
"Clenbuterol is a beta(2)-agonist and potent selective bronchodilator that is used to treat bronchospasm in the horse. "( Clenbuterol and the horse revisited.
Kearns, CF; McKeever, KH, 2009
)
3.24
"Clenbuterol is a potent, long-acting beta-adrenergic agonist that has been reported as an adulterant of heroin. "( A novel neuromuscular syndrome associated with clenbuterol-tainted heroin.
Hoffman, RS; Kirrane, B; Labinson, RM; Manini, A; Nelson, LS; Rao, R; Stajic, M, 2008
)
2.05
"Clenbuterol is a well-known growth promoter, illegally used in farm animals, especially in cattle. "( Clenbuterol storage stability in the bovine urine and liver samples used for European official control in the azores islands (portugal).
Barbosa, J; da Silveira, MI; Ferreira, H; Jesuino, B; Matos, J; Pinheiro, I; Ramos, F, 2009
)
3.24
"Clenbuterol is a β(2)-adrenergic receptor agonist licensed for veterinary use as a bronchodilator. "( Clenbuterol toxicosis in three Quarter Horse racehorses after administration of a compounded product.
Barker, SA; Bauer, RW; McConnico, RS; Mirza, MH; Morgan, TW; Thompson, JA, 2011
)
3.25
"Clenbuterol is a ß-adrenergic agonist with low specificity, with some veterinary indications."( [Adrenergic beta-agonist intoxication].
Alexandrino, MB; Carrola, P; Devesa, N; Moura, JJ; Ramos, F; Silva, JM,
)
0.85
"Clenbuterol is an orally administered long-acting beta-2 adrenergic agonist closely related to albuterol that, in recent years, has become a substance of abuse in the bodybuilding and athletic community."( Myocardial ischemia associated with clenbuterol abuse: report of two cases.
Huckins, DS; Lemons, MF, 2013
)
2.11
"Clenbuterol is a repartition agent (beta 2-adrenoceptor agonist) that can decrease fat deposition and increase skeletal muscle growth at manageable dose. "( Identifying lipid metabolism genes in pig liver after clenbuterol administration.
Guo, W; Hu, X; Li, N; Liu, Q; Zhang, J; Zhao, Y, 2012
)
2.07
"Clenbuterol is a long-lasting β-adrenoceptor (β-AR) agonist and was once medicated as a bronchial dilatator, and is also used by body-building enthusiasts and athletes and in livestock breeding because of its anabolic effect on skeletal muscles and ability to promote lipolysis. "( Acute clenbuterol induces hypotension, atrioventricular block and cardiac asystole in the rabbit.
Cao, JM; Dong, R; Fu, LL; Guo, JF; Hong, XF; Ke, Y; Liu, Y; Xu, TM, 2013
)
2.31
"Clenbuterol is a β2 agonist agent with anabolic properties given by the increase in the muscular mass in parallel to the decrease of the body fat. "( Quantification of clenbuterol at trace level in human urine by ultra-high pressure liquid chromatography-tandem mass spectrometry.
Badoud, F; Baume, N; Dvorak, J; Nicoli, R; Petrou, M; Saugy, M, 2013
)
2.17
"Clenbuterol (CLB) is a kind of β2-adrenergic agonists which was illegally used as feed additives nowadays. "( Investigation on potential enzyme toxicity of clenbuterol to trypsin.
Chai, J; Dai, J; Liu, R; Xu, Q, 2013
)
2.09
"Clenbuterol (CBL) is a potent beta(2)-adrenoceptor agonist used for the management of respiratory disorders in the horse. "( Quantification of clenbuterol in equine plasma, urine and tissue by liquid chromatography coupled on-line with quadrupole time-of-flight mass spectrometry.
Birks, EK; Guan, F; Li, R; Luo, Y; Rudy, JA; Soma, LR; Teleis, D; Tsang, DS; Uboh, CE, 2002
)
2.09
"Clenbuterol is a beta2-adrenoceptor agonist primarily used for treating bronchospasm and alleviating the symptoms of chronic obstructive pulmonary disease (COPD) in the horse. "( Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses.
Kearns, CF; Lynch, GS; McKeever, KH; Plant, DR, 2003
)
2.14
"Clenbuterol is a long-acting B-2 agonist used in veterinary medicine."( Clenbuterol toxicity: an emerging epidemic. A case report and review.
Bilkoo, P; Kagaoan, G; Riddle, CD; Thomas, J, 2007
)
2.5
"Clenbuterol is a long-acting beta2-adrenergic agonist primarily used in veterinary medicine in the United States. "( Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation.
Aaron, C; Daubert, GP; Leung, VW; Mabasa, VH, 2007
)
2.26
"Clenbuterol (CLB) is an antiasthmatic drug used also illegally as a lean muscle mass enhancer in both humans and animals. "( Formation of an adduct by clenbuterol, a beta-adrenoceptor agonist drug, and serum albumin in human saliva at the acidic pH of the stomach: evidence for an aryl radical-based process.
Brambilla, G; Camerini, S; Crescenzi, M; Loizzo, A; Minetti, M; Peri, L; Pietraforte, D; Scorza, G, 2008
)
2.09
"Clenbuterol is an effective bronchodilator and, on the basis of molecular weight, about ten times more potent than salbutamol when given by aerosol."( A comparison between inhaled clenbuterol and salbutamol in chronic bronchitis with reversible airway obstruction.
Baronti, A; Grieco, A; Vibelli, C, 1980
)
1.27
"Clenbuterol (C.) is a bronchospasmolytic agent which selectively stimulates beta 2-receptors; side-effects of the drug are virtually minimal. "( Clenbuterol--a long term uterine relaxant.
Krumbachner, G; Zahn, V, 1981
)
3.15
"Clenbuterol is a recently popular drug used by athletes in many sports for its purported anabolic effects and reduction of subcutaneous fat. "( Clenbuterol: a substitute for anabolic steroids?
Brown, DE; North, P; Prather, ID; Wilson, JR, 1995
)
3.18
"Clenbuterol proved to be a useful drug for manual correction of dystocias in cattle."( The use of clenbuterol in large animal obstetrics: manual correction of bovine dystocias.
Ménard, L, 1994
)
1.4
"Clenbuterol is a beta-agonist drug used illegally as a growth stimulant in meat-producing animals and human athletes. "( Analysis of clenbuterol in human plasma using liquid chromatography/atmospheric-pressure chemical-ionization mass spectrometry.
Bajic, S; Doerge, DR; Lowes, S, 1993
)
2.11
"Clenbuterol is a beta 2-agonist drug which in some countries is used illegally to enhance the productivity of various food-producing species, including poultry. "( Changes in the activities of hepatic xenobiotic metabolising enzymes after the administration of clenbuterol to female broilers.
Ceppa, L; Dacasto, M; Nebbia, C; Roncada, P, 1996
)
1.95
"Clenbuterol is a beta-adrenergic agonist widely but illegally used in cattle as a growth promoter. "( Evidence for a new and major metabolic pathway clenbuterol involving in vivo formation of an N-hydroxyarylamine.
Bories, G; Debrauwer, L; Tulliez, J; Zalko, D, 1997
)
2
"Clenbuterol HCl is a beta-adrenergic agonist that has been used illegally in Europe and the United States by some livestock producers to increase carcass leanness. "( Distribution, elimination, and residues of [14C]clenbuterol HCl in Holstein calves.
Paulson, GD; Smith, DJ, 1997
)
2
"Clenbuterol (CBL) is a member of the class of drugs called beta-agonists, which have powerful desirable and undesirable effects. "( Illegal use of beta-adrenergic agonists in the United States.
Dunnavan, G; Mitchell, GA, 1998
)
1.74
"Clenbuterol is a beta 2-agonist with anabolic properties that has not been seen previously with myocardial infarction."( Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms.
Dobbs, T; Goldstein, DR; Krull, B; Plumb, VJ, 1998
)
2.46
"Clenbuterol is a relatively selective beta2-adrenergic partial agonist that has bronchodilator activity. "( Beta-agonist-induced alterations in organ weights and protein content: comparison of racemic clenbuterol and its enantiomers.
Aboul-Enein, HY; Abukhalaf, IK; Oster, RA; Parks, BA; Paulsen, DF; Pitts, SA; Potter, DE; von Deutsch, DA; Wineski, LE, 2000
)
1.97
"Clenbuterol is a beta2 agonist/antagonist bronchodilator marketed as Ventipulmin and is the only member of this group of drugs approved by the US Food and Drug Administration (FDA) for use in horses. "( Clenbuterol in the horse: urinary concentrations determined by ELISA and GC/MS after clinical doses.
Fisher, M; Harkins, JD; Lehner, AF; Tobin, T; Woods, WE, 2001
)
3.2
"Clenbuterol is a beta2 agonist/antagonist bronchodilator, and its identification in post-race samples may lead to sanctions. "( Clenbuterol in the horse: confirmation and quantitation of serum clenbuterol by LC-MS-MS after oral and intratracheal administration.
Dirikolu, L; Fisher, M; Harkins, JD; Karpiesiuk, W; Lehner, AF; Robinson, NE; Tobin, T; Woods, WE,
)
3.02
"Clenbuterol (CBL) is an orally active beta2-adrenoceptor agonist which has been used in veterinary medicine as a broncodilator and an agent of uterine relaxation. "( Determination of clenbuterol residues in bovine urine by optical immunobiosensor assay.
Baxter, GA; Bjurling, P; Elliott, CT; Haughey, SA; Jonson, C; Persson, B,
)
1.91
"Clenbuterol is a long acting beta2-adrenergic agonist used in the treatment of pulmonary disorders. "( Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels.
Freyberg, CL; Hoffman, RJ; Hoffman, RS; Nelson, LS; Poppenga, RH, 2001
)
3.2
"Clenbuterol is a beta 2-sympathomimetic bronchodilator. "( A trial of clenbuterol in bronchial asthma.
Anderson, G; Wilkins, E, 1977
)
2.09
"Clenbuterol is a beta-2-sympathicomimetic, from a series of substituted phenylethanolamines, and it is characterised by good absorption and prolonged action after systemic administration."( Dose response relationship of clenbuterol (NAB 365) as a solution for inhalation.
Herzog, H; Perruchoud, A; Tschan, M, 1979
)
1.27
"Clenbuterol is a betamimetic agent with a marked effect on the adrenergic beta-2-receptors relevant for tocolysis. "( [Oral tocolytic therapy with clenbuterol--clinical facts].
Hermer, M; Kanitz, T; Meinen, K; Rahn, M; Rominger, KL,
)
1.87

Effects

Clenbuterol has been shown to reverse pathologic cardiac remodeling during left ventricular assist device (LVAD) support, leading to restored ventricular function and explantation of LVAD devices. The drug can increase muscle mass and residues in tissue of treated animals but can cause symptoms of acute poisoning in people.

ExcerptReferenceRelevance
"Clenbuterol has been used to alleviate chronic obstructive pulmonary disease and elicit an anabolic response in muscles. "( Negative effect of clenbuterol on physical capacities and neuromuscular control of muscle atrophy in adult rats.
Bisson, JF; Dernoncourt, V; Lang, G, 2015
)
2.19
"Clenbuterol has previously been described in case reports to be cardiotoxic, with patient presentations similar to overdoses of sympathomimetic substances, but reports of rhabdomyolysis are limited to a single case series in horses."( Rhabdomyolysis Secondary to Clenbuterol Use and Exercise.
Bursua, A; Gimbar, RP; Grimmer, NM; Patel, M, 2016
)
1.45
"Clenbuterol has well-described cardiotoxic effects, and we report the additional toxicity of rhabdomyolysis with its use."( Rhabdomyolysis Secondary to Clenbuterol Use and Exercise.
Bursua, A; Gimbar, RP; Grimmer, NM; Patel, M, 2016
)
1.45
"Clenbuterol has recently been shown to reverse pathologic cardiac remodeling during left ventricular assist device (LVAD) support, leading to restored ventricular function and explantation of LVAD devices. "( Effect of clenbuterol administration on the healthy murine heart.
Anderson, M; Larson, D; Moore, D, 2008
)
2.19
"Clenbuterol has favorable effects in the treatment of rat cerebral vasospasm (CVS). "( The effects of clenbuterol on cerebral vasospasm in an experimental rat model of subarachnoid hemorrhage.
Acar, F; Benek, B; Cirak, B; Coskun, E; Ozcakar, L; Suzer, T; Tahta, K; Yalcin, N, 2011
)
2.16
"Clenbuterol, too, has essentially weaker calorigenic effects than isoprenaline."( [Calorigenic action of beta-sympathomimetics].
Ankermann, H, 1982
)
0.99
"Clenbuterol has the ability to increase muscle mass and residues in tissue of treated animals but can cause symptoms of acute poisoning in people."( Illegal use of beta-adrenergic agonists in the United States.
Dunnavan, G; Mitchell, GA, 1998
)
1.02
"1. Clenbuterol has been proposed for the treatment of muscle wasting disorders, but its long-term effects on skeletal muscle function have not been tested rigorously. "( Year-long clenbuterol treatment of mice increases mass, but not specific force or normalized power, of skeletal muscles.
Faulkner, JA; Hinkle, RT; Lynch, GS, 1999
)
1.33
"Clenbuterol has shown a neuroprotective action in the central nervous system by induction of growth factors after cellular damage. "( [The influence on nerve regeneration by the beta2-receptor agonist clenbuterol].
Fansa, H; Frerichs, O; Keilhoff, G; Schneider, W; Ziems, P, 2002
)
1.99
"Clenbuterol has been shown to ameliorate denervation-induced atrophy and, therefore, clearly has therapeutic potential in the treatment of muscle wasting conditions in man. "( Denervation increases clenbuterol sensitivity in muscle from young rats.
Baillie, AG; Delday, MI; Hay, SM; Maltin, CA, 1992
)
2.04

Actions

Clenbuterol (CL), which promotes the growth of muscular tissue and the reduction of body fat in pigs and cattle, has been confirmed to be a potential hazard to human health. The clen buterol-induced increase in muscle growth was concomitant with qualitative changes in the muscle's proteome that need to be considered when proposing therapeutic uses for this agent.

ExcerptReferenceRelevance
"Clenbuterol (CL), which promotes the growth of muscular tissue and the reduction of body fat in pigs and cattle, has been confirmed to be a potential hazard to human health. "( Coupling purification and in situ immobilization process of monoclonal antibodies to clenbuterol for immunosensor application.
Cao, H; Wang, L; Xu, F; Yu, J; Yuan, M, 2015
)
2.08
"Clenbuterol led to a 30% increase in CD31(+) cells in the bone marrow of MLP(-/-) heart failure mice (p < 0.004)."( Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy.
Adhikari, N; Barton, PJ; Birks, EJ; Charles, NJ; Hall, JL; Lee, S; Mariash, A; Miller, LW; Polster, SP; Rider, JE; Smolenski, RT; Stangland, J; Tadros, G; Terracciano, CM; Yacoub, MH, 2009
)
1.38
"The clenbuterol-induced increase in muscle growth was concomitant with qualitative changes in the muscle's proteome that need to be considered when proposing therapeutic uses for this agent."( Anabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscle.
Beynon, RJ; Burniston, JG; Goldspink, DF; McLean, L, 2007
)
1.05
"The clenbuterol-induced increase in PGC-1alpha mRNA expression in mice was inhibited by pretreatment with the beta-AR antagonist propranolol."( An increase in murine skeletal muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) mRNA in response to exercise is mediated by beta-adrenergic receptor activation.
Ezaki, O; Goto, M; Kai, Y; Kawanaka, K; Minokoshi, Y; Miura, S; Shiuchi, T; Tamura, M, 2007
)
0.82
"Clenbuterol, which may cause symptoms of increased heart rate, muscular tremors, headache, nausea, and muscular cramps in patients, has been prohibited for consumption in many countries including the European Union, the United States, and China. "( Screening procedures for clenbuterol residue determination in raw swine livers using lateral-flow assay and enzyme-linked immunosorbent assay.
Fung, DY; Lai, WH; Xiong, YH; Xu, Y, 2008
)
2.09
"Clenbuterol is known to increase muscle mass in nonburned and burn-injured subjects. "( Beneficial wound healing and metabolic effects of clenbuterol in burned and nonburned rats.
Barrow, RE; Herndon, DN; Hollyoak, MA; Meyers, NA; Muller, MJ; Williams, WG,
)
1.83
"The clenbuterol-induced increase in muscle protein was accompanied by an inhibition of the Ca-dependent protease activity and an increase of muscle DNA- and RNA-content."( [Effect of a beta-agonist and a beta-agonist/beta-antagonist combination on muscle growth, body composition and protein metabolism in rats].
Krawielitzki, K; Rehfeldt, C; Reichel, K; Schadereit, R; Weikard, R, 1993
)
0.77
"Clenbuterol caused an increase in muscle growth, accompanied by a reduction in beta 2-adrenoceptor density in the rat hind-limb."( Effects of clenbuterol, ICI118551 and sotalol on the growth of cardiac and skeletal muscle and on beta 2-adrenoceptor density in female rats.
Lindsay, DB; Matthews, ML; Pegg, GG; Sillence, MN; Spiers, WG, 1991
)
1.39
"Clenbuterol did not increase the basal rate of insulin secretion (4 mM glucose) in human islets."( Differential effects of beta-adrenergic agonists on insulin secretion from pancreatic islets isolated from rat and man.
Berrow, NS; James, RF; Lacey, RJ; Lake, SP; London, NJ; Morgan, NG; Scarpello, JH, 1990
)
1
"With clenbuterol an increase in bronchial artery flow was accompanied by a decrease in systemic blood pressure, indicating bronchial arterial vasodilatation."( Action of sympathomimetic drugs on the bronchial circulation of the horse.
Dobson, A; Gleed, RD; Hackett, RP; Sanders, EA, 1991
)
0.74
"Clenbuterol was active at lower doses than isoproterenol and salbutamol, a result which is consistent with its better penetration in the central nervous system."( Antinociceptive activity of beta-adrenoceptor agonists in the hot plate test in mice.
Brochet, D; Martin, P; Micó, JA; Simon, P, 1986
)
0.99
"The clenbuterol-induced increase in muscle growth in the insulin-replaced diabetic rats indicated that this beta-adrenergic agonist effect was not mediated by an alteration of circulating levels of insulin, secondary to beta-agonist action on pancreatic insulin release."( Clenbuterol-induced muscle growth: investigation of possible mediation by insulin.
Barreto, A; Chaung, LY; McElligott, MA; Mulder, JE, 1987
)
2.2

Treatment

Clenbuterol treatment resulted in a slower rate of pH decline in the unstimulated longissimus muscle but did not affect the ultimate pH. The drug also reduced the proportion of small diameter fibres, and therefore an increase in mean fibre diameter.

ExcerptReferenceRelevance
"Clenbuterol treatment resulted in an increase in total bodyweight, growth rate and in quadriceps skeletal muscle mass. "( Beta2-adrenergic agonist-induced hypertrophy of the quadriceps skeletal muscle does not modulate disease severity in the rodent meniscectomy model of osteoarthritis.
Bardsley, R; Doherty, M; Jones, SW; Maciewicz, RA; Parr, T; Tonge, DP, 2010
)
1.8
"Clenbuterol treatment activated cAMP response element binding protein within retrogradely traced neurons which has been associated with axonal regrowth."( Partial functional recovery after complete spinal cord transection by combined chondroitinase and clenbuterol treatment.
Bai, F; Etlinger, JD; Peng, H; Zeman, RJ, 2010
)
1.3
"Clenbuterol treatment induced rapid development of cardiac hypertrophy with increased muscle mass at day 1 and elevated heart rate and QT interval throughout the 28-day period."( A gene expression profile of the myocardial response to clenbuterol.
Barton, PJ; Felkin, LE; Lara-Pezzi, E; Smolenski, RT; Soppa, GK; Terracciano, CM; Yacoub, MH, 2009
)
1.32
"Clenbuterol treatment in MLP(-/-) mice was associated with significant changes in the following circulating factors: tissue inhibitor of metalloproteinase-type 1, leukemia inhibitory factor 1, C-reactive protein, apolipoprotein A1, fibroblast growth factor 2, serum glutamic oxaloacetic transaminase, macrophage-derived chemokine, and monocyte chemoattractant protein-3."( Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy.
Adhikari, N; Barton, PJ; Birks, EJ; Charles, NJ; Hall, JL; Lee, S; Mariash, A; Miller, LW; Polster, SP; Rider, JE; Smolenski, RT; Stangland, J; Tadros, G; Terracciano, CM; Yacoub, MH, 2009
)
1.38
"Clenbuterol treatment resulted in increased cell size of cardiac myocytes with increased protein accumulation and myofibrillar organisation characteristic of hypertrophic growth."( Clenbuterol induces cardiac myocyte hypertrophy via paracrine signalling and fibroblast-derived IGF-1.
Barton, PJ; Bhavsar, PK; Brand, NJ; Cullen, ME; Felkin, LE; Luther, PK; Yacoub, MH, 2010
)
2.52
"Clenbuterol pretreatment provides significant cardioprotection against ischaemia/reperfusion injury and this is mediated by the beta(2)-adrenoceptor-G(i)-protein signalling. "( Beta(2)-adrenoceptor agonist clenbuterol reduces infarct size and myocardial apoptosis after myocardial ischaemia/reperfusion in anaesthetized rats.
Feng, M; Fu, Q; Hu, B; Liu, H; Wang, X; Xiang, J; Zhang, Q, 2010
)
2.09
"Clenbuterol treated pigs were randomly sacrificed (n=3) on days 0, 3, 7 and 14 of treatment discontinuation and clenbuterol residues determined in muscle tissue."( Clenbuterol residues in pig muscle after repeat administration in a growth-promoting dose.
Persi, N; Pleadin, J; Vahcić, N; Vulić, A, 2010
)
2.52
"Clenbuterol-treated pigs were randomly sacrificed (n = 3) on days 0 and 45 of treatment discontinuation, and clenbuterol residues were determined in retinal tissue dissected from the eye."( Determination of clenbuterol residues in retinal tissue of food-producing pigs.
Milić, D; Mitak, M; Perši, N; Pleadin, J; Vulić, A, 2011
)
1.43
"Clenbuterol treatment, 2 x 0.8 microg/kg/day i.v."( Regulation of equine lymphocyte beta-adrenoceptors under the influence of clenbuterol and dexamethasone.
Abraham, G; Brodde, OE; Ungemach, FR, 2002
)
1.27
"Clenbuterol treatment increased fiber cross-sectional area (CSA) by 6% and maximal isometric force (P(o)) by 20% in extensor digitorum longus (EDL) muscles, whereas fiber CSA in soleus muscles decreased by 3% and P(o) was unchanged, compared with untreated controls."( Beta 2-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol.
Gregorevic, P; Lynch, GS; Plant, DR; Ryall, JG; Sillence, MN, 2002
)
1.25
"The clenbuterol treatment had a clear effect on the thymocyte size, decreasing their mean nuclear area."( Quantitative changes in the normal and apoptotic thymocytes of pigs treated with anabolic doses of the beta2 adrenergic agonist clenbuterol.
Artacho-Pérula, E; Blanco, A; Flores-Acuña, R; Monterde, JG; Moyano, R, 2003
)
1.01
"Clenbuterol treatment decreased Asb-15 mRNA in skeletal muscle at 12 and 24 h (P < 0.01) and also decreased mRNA in lung at 12 h (P < 0.05)."( Altered mRNA abundance of ASB15 and four other genes in skeletal muscle following administration of beta-adrenergic receptor agonists.
Hancock, DL; McDaneld, TG; Moody, DE, 2004
)
1.04
"Both clenbuterol and cimaterol treatments caused a downregulation in testicular androgen receptors and in pulmonary, cardiac and central nervous system beta-adrenergic receptors."( Effect of dietary clenbuterol and cimaterol on muscle composition, beta-adrenergic and androgen receptor concentrations in broiler chickens.
Badino, P; Cuniberti, B; Lussiana, C; Odore, R; Pagliasso, S; Perona, G; Schiavone, A; Tarantola, M, 2004
)
1.11
"Clenbuterol treatment further reduced bone mineral density."( Severe bone alterations under beta2 agonist treatments: bone mass, microarchitecture and strength analyses in female rats.
Arlettaz, A; Benhamou, CL; Bonnet, N; Brunet-Imbault, B; Collomp, K; Courteix, D; Horcajada, MN; Richard, O; Vico, L, 2005
)
1.05
"Clenbuterol treatment induced growth by 27-41% in normal rats and attenuated muscle loss during hindlimb suspension by 10-20%."( Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol.
Bodine, SC; Kline, WO; Panaro, FJ; Yang, H, 2007
)
1.3
"Clenbuterol treatment improved in vivo LV function measured with echocardiography (LVEF (%): HF 35.9 +/- 2 [16], HF + Clen 52.1 +/- 1.4 [16]; P < 0.001; mean +/- SEM [n])."( Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure.
Barton, PJ; Felkin, LE; Lee, J; Siedlecka, U; Soppa, GK; Stagg, MA; Terracciano, CM; Yacoub, MH; Youssef, S, 2008
)
1.35
"Clenbuterol treatment of failing rat hearts, alone or in combination with mechanical unloading, improves LV function at the whole-heart and cellular levels by affecting cell morphology, excitation-contraction coupling, and myofilament sensitivity to calcium. "( Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure.
Barton, PJ; Felkin, LE; Lee, J; Siedlecka, U; Soppa, GK; Stagg, MA; Terracciano, CM; Yacoub, MH; Youssef, S, 2008
)
2.07
"Clenbuterol treatment was associated with a 30-40% increase in fatigability in DIA and SOL muscles of control and mdx mice at both ages."( Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice.
Dupont-Versteegden, EE; Katz, MS; McCarter, RJ, 1995
)
1.26
"Clenbuterol treatment did, however, increase citrate synthase activity and GLUT-4 protein in soleus."( Fiber type-specific effects of clenbuterol and exercise training on insulin-resistant muscle.
Etgen, GJ; Ivy, JL; Kang, HY; Torgan, CE, 1995
)
1.3
"Clenbuterol treatment had no statistically significant effect on accumulated food intake or body composition in the adult mice."( The effect of clenbuterol on body composition in spontaneously eating tumour-bearing mice.
Hyltander, A; Lundholm, K; Svaninger, G, 1993
)
1.37
"Clenbuterol and estradiol treatments induced a significant increase in uterus weight and in relative uterus weight, whereas in the groups treated with propranolol and clenbuterol plus propranolol no differences were detected versus controls."( Regulation of uterine estrogen receptors (ER) by beta-adrenergic stimulation in immature rats.
Badino, P; Dacasto, M; Di Carlo, F; Girardi, C; Re, G, 1993
)
1.01
"Clenbuterol treatment induced significant (P < 0.05) increase in uterine estrogen receptor concentration of rats treated with the 2 higher doses."( Effects of long-term administration of clenbuterol in mature female rats.
Badino, P; Biolatti, B; Dacasto, M; Di Carlo, F; Girardi, C; Nebbia, C; Re, G, 1993
)
1.28
"Clenbuterol treatment resulted in a slower rate of pH decline in the unstimulated longissimus muscle but did not affect the ultimate pH."( Effects on meat quality of the use of clenbuterol in veal calves.
Breukink, HJ; Geesink, GH; Smulders, FJ; van der Kolk, JH; van Laack, HL; Wensing, T, 1993
)
1.28
"Clenbuterol treatment resulted in a reduction in the proportion of small diameter fibres, and therefore an increase in mean fibre diameter, in dystrophic EDL."( Effect of the beta 2-adrenergic agonist clenbuterol on the growth of fast- and slow-twitch skeletal muscle of the dystrophic (C57BL6J dy2J/dy2J) mouse.
Agbenyega, ET; Hatton, PA; Morton, RH; Wareham, AC, 1995
)
1.28
"Clenbuterol treatment induced a significant (P < 0.01) down-regulation of beta-AR subtypes (beta 1-AR, beta 2-AR, myometrial high-affinity beta 2-AR, and ovarian low-affinity beta 2-AR)."( Down-regulation of beta-adrenergic receptors and up-regulation of estrogen and progesterone receptors induced in the reproductive system of female veal calves by dietary clenbuterol.
Badino, P; Girardi, C; Novelli, A; Re, G, 1995
)
1.21
"Clenbuterol treatment prevented the increase in neuronal firing without altering lesion induction or the loss of complex spikes, and propranolol treatment produced a partial reversal of the inhibitory effect of clenbuterol on the neuronal firing rate."( Adrenergic agents inhibit rapid increases in cerebellar Purkinje cell glutamic acid decarboxylase (GAD67) mRNA levels after climbing fiber lesions or reserpine treatment.
Billitz, MS; Drengler, SM; Lorden, JF; Oltmans, GA, 1996
)
1.02
"Clenbuterol treatment induced 26% left ventricular hypertrophy. "( Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features.
Bishop, J; Boheler, KR; Petrou, M; Wong, K; Yacoub, MH, 1998
)
3.19
"Clenbuterol treatment significantly increased the relative mass (P<0.001) and relative tetanic force production (P<0.01) of the soleus of dystrophic animals, most likely due to increases in protein accretion and improved regeneration."( Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol.
Hayes, A; Williams, DA, 1998
)
1.24
"Clenbuterol-treated rats also showed a reduction in growth when compared to P rats (P = 3.2 +/- 1.1 vs CL = -10.2 +/- 1.9 g, P < 0.05)."( Increase in skeletal muscle protein content by the beta-2 selective adrenergic agonist clenbuterol exacerbates hypoalbuminemia in rats fed a low-protein diet.
Lunn, PG; Sawaya, AL, 1998
)
1.24
"3. Clenbuterol treatment increased the absolute mass of each muscle tested: the heart by 28%, extensor digitorum longus (EDL) by 16%, soleus by 22% and tibialis anterior by 17%."( Year-long clenbuterol treatment of mice increases mass, but not specific force or normalized power, of skeletal muscles.
Faulkner, JA; Hinkle, RT; Lynch, GS, 1999
)
1.22
"Clenbuterol treatment was associated with dislodgment of the fixed embryo in only 1 of 5 mares."( Effect of oxytocin, prostaglandin F2 alpha, and clenbuterol on uterine dynamics in mares.
Gastal, EL; Gastal, MO; Ginther, OJ; Torres, CA, 1998
)
1.28
"Clenbuterol treatment did not increase the normalized force or power output of diaphragm strips from either mdx or control mice."( Force and power output of diaphragm muscle strips from mdx and control mice after clenbuterol treatment.
Faulkner, JA; Hinkle, RT; Lynch, GS, 2001
)
1.26
"Clenbuterol treatment during pulmonary artery banding improves systolic function of the chronically pressure-overloaded right ventricle. "( Influence of clenbuterol treatment during six weeks of chronic right ventricular pressure overload as studied with pressure-volume analysis.
Hon, JK; Petrou, M; Steendijk, P; Wong, K; Yacoub, MH, 2001
)
2.12
"Clenbuterol treatment had no direct effect on insulin-stimulated glucose uptake."( Clenbuterol prevents epinephrine from antagonizing insulin-stimulated muscle glucose uptake.
Ding, Z; Hunt, DG; Ivy, JL, 2002
)
2.48
"Clenbuterol treatment for several weeks prevented up to one-third of the reduction in mineralization of femurs and tibias caused by sectioning of the sciatic nerve in young rats. "( Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated hindlimbs.
Etlinger, JD; Guo, G; Hirschman, A; Hirschman, ML; Zeman, RJ, 1991
)
3.17
"Clenbuterol treatment increased the weight of skeletal muscles 22% to 39% in 3-month-old rats, 19% to 35% in 12-month-old rats, and 22% to 25% in 23-month-old animals."( Effects of clenbuterol on skeletal muscle mass, body composition, and recovery from surgical stress in senescent rats.
Carter, WJ; Dang, AQ; Faas, FH; Lynch, ME, 1991
)
1.39
"Clenbuterol treatment decreased the vasodilatory responses to the beta-adrenoceptor agonist isoprenaline and adenosine, agents which act through an increase in intracellular cyclic AMP."( Effects of clenbuterol treatment on the responses to vasodilators in urethane-anaesthetized rats.
Enero, MA; Gutkind, JS; Kazanietz, MG, 1990
)
1.39
"Clenbuterol treatment produced desensitization of the beta 2-adrenoceptor-mediated effect and thus reduced the vasodilator response induced by isoproterenol and increased the vasoconstriction produced by epinephrine but not that caused by NE."( Pressor response induced by clenbuterol treatment in immobilized normotensive rats.
Armando, I; Enero, MA; Gutkind, JS; Kazanietz, MG; Puyó, A, 1989
)
1.29
"1. Clenbuterol treatment in innervated and denervated phasic extensor digitorum longus, plantaris and gastrocnemius muscles from rats caused a significant increase in RNA and protein contents in all muscles except denervated extensor digitorum longus. "( The action of the beta-agonist clenbuterol on protein metabolism in innervated and denervated phasic muscles.
Delday, MI; Hay, SM; Lobley, GE; Maltin, CA; Reeds, PJ, 1989
)
1.18
"Treatment with clenbuterol attenuated all IL-1β-induced changes in the striatum including MBS-2 immunoreactivity and TUNEL + staining."( The β
Boyle, N; Connor, T; Griffin, ÉW; Harkin, A; Harper, P; O'Neill, E; Ryan, KJ; Yssel, JD, 2018
)
0.82
"Treatment with clenbuterol modestly attenuates the deleterious effects of this long-distance transportation model on tracheal mucociliary clearance."( Effect of clenbuterol on tracheal mucociliary transport in horses undergoing simulated long-distance transportation.
Boston, R; Chen, JW; Jackson, K; Nolen-Walston, RD; Norton, JL,
)
0.89
"When treated with clenbuterol, the nonworking horses had a similar mean change in PBF from baseline from day 6 onward, which peaked at -0.75% on day 18 (an 8% decrease in PBF)."( Effect of long-term oral administration of a low dosage of clenbuterol on body fat percentage in working and nonworking adult horses.
Barr, CA; Boston, RC; Moore, CM; Nolen-Walston, RD; Soma, LR; Tomlinson, JE, 2015
)
0.98
"Treatment with clenbuterol, a beta(2)-adrenoceptor agonist that can enhance regeneration of motor neuron axons, opposed the development of motor deficits in parallel with a reduced proportion of motor neurons with eccentric nuclei consistent with improved synaptic function."( Clenbuterol retards loss of motor function in motor neuron degeneration mice.
Etlinger, JD; Peng, H; Zeman, RJ, 2004
)
2.11
"Treatment with clenbuterol increased SOD activity and decreased the MDA level and LDH release compared with the I/R group (P<0.05)."( Effect of beta2-adrenergic agonist clenbuterol on ischemia/reperfusion injury in isolated rat hearts and cardiomyocyte apoptosis induced by hydrogen peroxide.
Fu, Q; Hu, BR; Liu, P; Xiang, JZ; Yang, L; Zhao, L, 2008
)
0.96
"Treatment with clenbuterol for 50 days increased succinic dehydrogenase negative (type IIB) and positive (types I and IIA) myofiber cross-sectional areas by 25%."( Bovine fast-twitch myosin light chain 1: cloning and mRNA amount in muscle of cattle treated with clenbuterol.
Davis, SK; Garcia, DK; Lunt, DK; Schiavetta, AM; Smith, SB; Stone, RT; Wilson, JJ; Wu, FY, 1995
)
0.85
"Pretreatment with clenbuterol did not change the glucagon-induced hyperglycaemia, but the serum levels of insulin were significantly higher."( Acute metabolic effects of clenbuterol in calves.
Jacobsson, SO; Luthman, J, 1993
)
0.91
"Pretreatment with clenbuterol (0.5 and 1.0 mg/kg) reduced the neuronal damage by 18.1% (P < 0.01) and 13.1% (P < 0.05), respectively."( Stimulation of beta2-adrenoceptors inhibits apoptosis in rat brain after transient forebrain ischemia.
Culmsee, C; Krieglstein, J; Semkova, I; Zhu, Y, 1998
)
0.62
"Treatment with clenbuterol (30 microg/kg, 100 microg/kg and 300 microg/kg; daily subcutaneous injection) significantly increased the NGF-LI and neuropeptide content of the sciatic nerve, with 30 microg/kg of clenbuterol normalising the levels in diabetic animals."( Clenbuterol stimulates neurotrophic support in streptozotocin-diabetic rats.
Riaz, SS; Tomlinson, DR, 1999
)
2.09
"Treatment with clenbuterol did not have any effects on the absorption of the dietary protein in any of the studies released."( The digestive and metabolic utilization of the dietary protein: effect of clenbuterol and protein level.
López, JA; Peréz-Llamas, F; Zamora, S,
)
0.7
"Treatment with clenbuterol did not alter any of these measurements in response to exercise."( Respiratory mechanics of horses during stepwise treadmill exercise tests, and the effect of clenbuterol pretreatment on them.
Bayly, WM; Covelli, G; Slocombe, RF, 1992
)
0.84
"2. Treatment with clenbuterol had a negative influence on body growth and feed efficiency when the animals were fed with low protein diets (4%)."( Influence of dietary protein level on growth: effect of clenbuterol.
Peréz-Llamas, F; Sastre, JF; Zamora, S, 1991
)
0.85
"Rats treated with clenbuterol for 18 days showed a 50% reduction in beta-receptor density, but the ratio of beta 1/beta 2-receptors was unaffected (15% beta 1/85% beta 2)."( Changes in tissue blood flow and beta-receptor density of skeletal muscle in rats treated with the beta2-adrenoceptor agonist clenbuterol.
Rothwell, NJ; Stock, MJ; Sudera, DK, 1987
)
0.8
"Treatment with clenbuterol caused changes only in calves with subacute bronchopneumonia; in these animals it decreased the total pulmonary resistance, the viscous work per litre and the peak to peak changes in transpulmonary pressure."( The effects of clenbuterol hydrochloride on the pulmonary function of calves with subacute and chronic bronchopneumonia.
Hajer, R, 1988
)
0.97

Toxicity

Clenbuterol was safe but less tolerable at the doses we selected compared with an earlier Italian case series. These results suggest that long-term clen Buterol treatment has a positive effect on muscle growth and force generation, but has adverse side effects.

ExcerptReferenceRelevance
" These results suggest that long-term clenbuterol treatment has a positive effect on muscle growth and force generation, but has adverse side effects such as increased muscle fatigability and development of deformities."( Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice.
Dupont-Versteegden, EE; Katz, MS; McCarter, RJ, 1995
)
0.81
" However, such doses may also induce myocyte death in the heart and skeletal muscles and hence may not be safe doses for humans."( Dose-dependent separation of the hypertrophic and myotoxic effects of the beta(2)-adrenergic receptor agonist clenbuterol in rat striated muscles.
Burniston, JG; Clark, WA; Goldspink, DF; Tan, LB, 2006
)
0.55
" Following consumption of meat or liver, intoxication cases were described, and cardiovascular toxic effects (tachycardia, hypertension) were of clinical relevance."( A pharmacodynamic study on clenbuterol-induced toxicity: beta1- and beta2-adrenoceptors involvement in guinea-pig tachycardia in an in vitro model.
Battinelli, L; Brambilla, G; Daniele, C; Di Sotto, A; Fiori, M; Loizzo, A; Loizzo, S; Mazzanti, G, 2007
)
0.64
" The toxic interaction of CLB with trypsin, an important digestive enzyme, was studied in vitro using multi-spectroscopic methods and molecular modeling methods."( Investigation on potential enzyme toxicity of clenbuterol to trypsin.
Chai, J; Dai, J; Liu, R; Xu, Q, 2013
)
0.65
" Information on clenbuterol associated adverse events is present in case reports and case series, though it may not be readily available."( Adverse events of clenbuterol among athletes: a systematic review of case reports and case series.
Kumari, S; Pal, B; Prabhakar, PK; Sahu, SK; Tewari, D, 2023
)
1.59
" Two participants experienced severe adverse events, neither related to the study."( Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis.
Bedlack, R; Koeberl, DD; Li, X; Lutz, MW, 2023
)
2.35
"Clenbuterol was safe but less tolerable at the doses we selected compared with an earlier Italian case series."( Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis.
Bedlack, R; Koeberl, DD; Li, X; Lutz, MW, 2023
)
3.8

Pharmacokinetics

The researchers used a proposed electrochemical biosensor to study the pharmacokinetics of clenbuterol. An initial rapid decline in the concentration of clen buterol in urine with a half-life of 10 h is followed by a slower elimination.

ExcerptReferenceRelevance
" Pharmacokinetic parameters were calculated by non-compartmental methods and submitted to statistical comparisons."( Steady-state bioavailability and pharmacokinetics of ambroxol and clenbuterol administered alone and combined in a new oral formulation.
Acerbi, D; Bizouard, J; Chiesi, P; Couet, W; Fourtillan, JB; Girault, J; Ingrand, I; Reigner, BG, 1989
)
0.51
" The plasma elimination half-life was 19."( Pharmacokinetics of clenbuterol in the ostrich.
Burger, WP; Toerien, S; van der Merwe, PJ, 1998
)
0.62
" These pharmacodynamic properties, and stronger lipophilic properties shown by the two compounds may result in increased cardiovascular risk for consumers of illicitly treated animals."( New beta-adrenergic agonists used illicitly as growth promoters in animal breeding: chemical and pharmacodynamic studies.
Boatto, G; Brambilla, G; Daniele, C; Loizzo, A; Manca, G; Mazzanti, G, 2003
)
0.32
" Serial plasma samples were collected and the pharmacokinetic behavior of each enantiomer in rats was characterized using a sequential achiral and chiral liquid chromatographic method."( Enantioselective pharmacokinetics of mabuterol in rats studied using sequential achiral and chiral HPLC.
Chen, H; Li, F; Liu, P; Lu, X; Qin, F, 2005
)
0.33
" We have further studied the pharmacokinetics of clenbuterol by using this proposed electrochemical biosensor, so a new tool to investigate pharmacokinetic is developed in this work."( An electrochemical biosensor for clenbuterol detection and pharmacokinetics investigation.
Bo, B; Jiang, B; Li, G; Lou, Y; Miao, P; Pei, D; Shu, Y; Zhu, X, 2013
)
0.93
"9 hours, while the tmax of 1-carbonyl trantinterol differed slightly."( Pharmacokinetics of trantinterol and its metabolite in healthy elderly and young subjects.
Huang, J; Huang, Z; Liu, G; Lu, Y; Pei, Q; Tan, H; Yang, G; Yuan, H, 2015
)
0.42
" Significant changes in Cmax and AUC of trantinterol and 1-carbony trantinterol were seen in the elderly and may be clinically important."( Pharmacokinetics of trantinterol and its metabolite in healthy elderly and young subjects.
Huang, J; Huang, Z; Liu, G; Lu, Y; Pei, Q; Tan, H; Yang, G; Yuan, H, 2015
)
0.42
" The method described herein was fully validated and successfully applied for the pharmacokinetic study of trantinterol in healthy volunteers after oral administration."( Quantification of trantinterol, its two metabolites and their primary conjugated metabolites in human plasma by ultra-high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Li, F; Li, K; Qin, F; Wang, L; Xiong, Z; Yin, B, 2016
)
0.43

Compound-Compound Interactions

A new pretreatment method, solid-phase extraction combined with dispersive liquid-liquid microextration (SPE-DLLME), was proposed in first time for the determination of clenbuterol (CLB) in porcine tissue samples. Administration of clen buterol either alone or in combination with GH increased the cross-sectional area of both fast twitch glycolytic (FG) and fast twitch oxidative glycoleytic (FOG) fibres.

ExcerptReferenceRelevance
" Administration of clenbuterol either alone or in combination with GH increased the cross-sectional area of both fast twitch glycolytic (FG), and fast twitch oxidative glycolytic (FOG) fibres in both muscles."( Effects of bovine pituitary growth hormone alone or in combination with the beta-agonist clenbuterol on muscle growth and composition in veal calves.
Delday, MI; Hay, SM; Innes, GM; Maltin, CA; Williams, PE, 1990
)
0.83
"A new pretreatment method, solid-phase extraction combined with dispersive liquid-liquid microextration (SPE-DLLME), was proposed in first time for the determination of clenbuterol (CLB) in porcine tissue samples."( Determination of clenbuterol in porcine tissues using solid-phase extraction combined with ultrasound-assisted dispersive liquid-liquid microextraction and HPLC-UV detection.
Geng, Y; Liu, B; Qiao, F; Yan, H, 2011
)
0.9
"Dispersive liquid-liquid microextraction based on solidification of floating organic drop (DLLME-SFO) was for the first time combined with field-amplified sample injection (FASI) in CE to determine four β(2)-agonists (cimbuterol, clenbuterol, mabuterol, and mapenterol) in bovine urine."( Dispersive liquid-liquid microextraction based on solidification of floating organic drop combined with field-amplified sample injection in capillary electrophoresis for the determination of beta(2)-agonists in bovine urine.
Alshana, U; Ertaş, N; Göğer, NG; Lubbad, I; Us, MF, 2013
)
0.57

Bioavailability

Clenbuterol hydrochloride is a beta-agonist with high potency, extended half-life, and bioavailability of 70% to 80%. In contrast, the increased potency of a ketone derivative might be explained by conversion in vivo to clen buterol.

ExcerptReferenceRelevance
" In contrast, the increased potency of a ketone derivative might be explained by conversion in vivo to clenbuterol, with increased bioavailability of this beta 2-agonist at the site of action."( Affinity of clenbuterol analogues for beta 2-adrenoceptors in bovine skeletal muscle and the effect of these compounds on urinary nitrogen excretion in female rats.
Lindsay, DB; Pegg, GG; Sillence, MN, 1991
)
0.88
" In summary, trantinterol is a potent noncompetitive P-gp inhibitor which may increase the bioavailability of other P-gp substrate drugs coadministered with it."( Trantinterol, a novel β2-adrenoceptor agonist, noncompetitively inhibits P-glycoprotein function in vitro and in vivo.
Fan, H; Fawcett, JP; Gu, J; Guo, Y; Liu, J; Ma, W; Sun, Y; Wang, T; Yang, J; Yang, Y; Yang, Z, 2015
)
0.42
"Clenbuterol hydrochloride is a beta-agonist with high potency, extended half-life, and bioavailability of 70% to 80%."( Chomping at the Bit: A Descriptive Report on Pediatric Clenbuterol Ingestion.
Akpunonu, P; Baum, RA; Mancuso, N; Rutter, PW; Woolum, J, 2020
)
2.25
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The effect of repeated administration of clenbuterol in a growth-promoting dose on hepatocellular integrity of female pigs was assessed. The presence of 10(-5) M ICI 118, 551, beta(2)-adrenoceptor antagonist, shifted significantly the clen buterol dose-response to 1 Hz electrical field stimulation (EC(50) 3.5).

ExcerptRelevanceReference
"The dose-response relationship of the new bronchodilator Clenbuterol (NAB 365, Boehringer Ingelheim) was tested in 12 patients with chronic obstructive lung disease."( Dose response relationship of clenbuterol (NAB 365) as a solution for inhalation.
Herzog, H; Perruchoud, A; Tschan, M, 1979
)
0.79
"Seven female Brown Swiss calves were used to study the pharmacokinetics of clenbuterol after an effective anabolic dosage of 5 micrograms/kg of BW was given twice daily for 3 wk."( The pharmacokinetics and residues of clenbuterol in veal calves.
Meyer, HH; Rinke, LM, 1991
)
0.78
" Redetermination of the dose-response function for clenbuterol, following 2 weeks of repeated daily administration, showed that clenbuterol no longer affected DRL behavior at doses up to 3 mg/kg."( Behavioral effects of beta adrenergic agonists and antidepressant drugs after down-regulation of beta-2 adrenergic receptors by clenbuterol.
O'Donnell, JM, 1990
)
0.74
"25 mg/kg), the dose-response curve of clenbuterol (0."( Does a single priming injection of clenbuterol alter behavioral response to beta-adrenoceptor agonists and antagonists in mice through a time-dependent process?
Martin, P; Simon, P; Soubrie, P, 1985
)
0.82
" Biotransformations are determined by environmental or genetic factors and by the associated therapy and can change dramatically from one patient to another (interindividual variability) or for the same patient by multiple dosing (intra-individual variability)."( [Metabolism of beta-adrenergic substances. Therapeutic implications].
Brès, J; Bressolle, F; Clauzel, AM; Pistre, MC; Rachmat, H,
)
0.13
" The characteristics of the oral route are easy usage, precise dosage and assured effects."( Oral beta 2-selective adrenergic bronchodilators.
Daniotti, S; Dottorini, M; Grassi, V; Schiassi, M; Tantucci, C, 1986
)
0.27
"1 micrograms/kg, ip) exerted effects opposite to those elicited by naloxone, that is, shifted the dose-response curve of clenbuterol to the right."( Opioid peptidergic systems modulate the activity of beta-adrenergic mechanisms during memory consolidation processes.
Baratti, CM; Introini-Collison, IB, 1986
)
0.48
" The applied dosage plan with clenbuterol tablets for oral therapy of premature labor proved to be ideal, both clinically as well as pharmacokinetically."( [Oral tocolytic therapy with clenbuterol--determination of the plasma level].
Hermer, M; Kanitz, T; Meinen, K; Rahn, M; Rominger, KL,
)
0.71
"The dose-response activity of clenbuterol, a new long-acting beta 2-agonist, was evaluated in 12 children aged 5 to 11 years with moderate to severe asthma."( Bronchodilating activity of oral clenbuterol in asthmatic children after single administration of different dosages.
Bennati, D; Boner, AL; Castellani, C; Schiassi, M; Sette, L,
)
0.7
" 10 micrograms of clenbuterol revealed no significant differences when compared to placebo, whereas the 20 micrograms dosage as usually administered in clinical routine demonstrated significant--but only slight--differences to placebo-baseline."( [Novel quantitative assessment of the tremorogenic effects of the beta 2-mimetics clenbuterol and salbutamol after oral administration].
Schaffler, K; Schuster, D, 1985
)
0.83
"-butyl-amino-ethanol hydrochloride (mabuterol) was tested in male rats dosed with 20, 100 and weekly increasing doses of 20, 40, 60, 80 and 100 mg/kg over 7 weeks."( Special toxicology--physical dependence potential, antigenicity and mutagenicity--of mabuterol.
Amemiya, K; Arika, T; Asano, T; Kudoh, M; Nakamura, M, 1984
)
0.27
" Nine patients participated in a dose-response study."( A comparison between inhaled clenbuterol and salbutamol in chronic bronchitis with reversible airway obstruction.
Baronti, A; Grieco, A; Vibelli, C, 1980
)
0.55
" Animals (n = 24) were dosed (10 micrograms/kg body weight) twice daily with clenbuterol for 21 days and slaughtered in groups of five (one untreated control animal per group) at 6 h and 1, 2, 4, 8 and 16 days after cessation of treatment."( Distribution and elimination of clenbuterol in tissues and fluids of calves following prolonged oral administration at a growth-promoting dose.
Dixon, SN; Limer, S; Pickett, RJ; Sauer, MJ, 1995
)
0.8
" In the rats dosed with propranolol and clenbuterol plus propranolol, no modifications occurred in estrogen receptor concentrations when compared with control values."( Regulation of uterine estrogen receptors (ER) by beta-adrenergic stimulation in immature rats.
Badino, P; Dacasto, M; Di Carlo, F; Girardi, C; Re, G, 1993
)
0.55
"Sample preparation procedures using octadecyl (C18) extraction disks were developed to obtain accurate and reproducible results for determinations of clenbuterol(20 micrograms per dose) and levothyroxine (100 micrograms per dose) in dissolution media of solid oral dosage forms."( Application of extraction disks in dissolution tests of clenbuterol and levothyroxine tablets by capillary electrophoresis.
Carducci, CN; Fernández Otero, GC; Lucangioli, SE; Rodríguez, VG, 1996
)
0.74
" The beta-2 selective adrenergic agonist clenbuterol produced an orderly dose-response relationship, and its discriminative stimulus effects were antagonized by the beta-adrenergic antagonist propranolol."( Effects of antidepressants in rats trained to discriminate the beta-2 adrenergic agonist clenbuterol.
Makhay, MM; O'Donnell, JM, 1999
)
0.79
" Analysis of plasma concentration enabled assessment of the extent of differences in pharmacokinetics between such dosing regimens."( Clenbuterol plasma pharmacokinetics in cattle.
Dave, M; Fallon, RJ; Sauer, MJ, 1998
)
1.74
" Urine and feces were collected during the dosing and the withdrawal period; edible and inedible tissues were collected at slaughter."( Total radioactive residues and clenbuterol residues in swine after dietary administration of [14C]clenbuterol for seven days and preslaughter withdrawal periods of zero, three, or seven days.
Smith, DJ, 2000
)
0.59
"Stereological methods were used to investigate the morphometric variations in the adrenal cell population of calves dosed orally with clenbuterol at an anabolic dose of 20 microg/kg bodyweight per day for 12 weeks."( Stereological study of the adrenal gland of calves treated with clenbuterol.
Artacho-Pérula, E; Blanco, A; Monterde, JG; Roldán-Villalobos, R, 2000
)
0.75
" Five horses were dosed with oral clenbuterol (0."( Clenbuterol in the horse: confirmation and quantitation of serum clenbuterol by LC-MS-MS after oral and intratracheal administration.
Dirikolu, L; Fisher, M; Harkins, JD; Karpiesiuk, W; Lehner, AF; Robinson, NE; Tobin, T; Woods, WE,
)
1.85
" The drug (a beta2-adrenoceptor agonist) was administered daily for six weeks by gastric gavage (10 microg/kg body weight), interrupted every 5 days by a 2 day omission of dosing to avoid drug desensitization."( Preservation of denervated muscle form and function by clenbuterol in a rat model of peripheral nerve injury.
Berry, MS; Fitton, AR; McGregor, AD, 2001
)
0.56
" In addition, 6 rats per group were dosed orally with 2 microg x kg(-1) clenbuterol daily acutely (1 dose) or chronically (1 dose daily for 8 days), or with distilled water to serve as controls."( Inhibition of the contractile responses of isolated human and rat bladders by clenbuterol.
Elliott, RA; Hudman, D; Norman, RI; Sandhu, DP; Terry, TR; Whitaker, P, 2001
)
0.77
" A significant inhibitory effect of clenbuterol on the electrical field stimulation evoked contractile response of rat detrusor muscle was observed after chronic but not acute oral dosing (p <0."( Inhibition of the contractile responses of isolated human and rat bladders by clenbuterol.
Elliott, RA; Hudman, D; Norman, RI; Sandhu, DP; Terry, TR; Whitaker, P, 2001
)
0.81
" Eight animals in each group received a daily oral dosage of 100 microg/kg bodyweight during four, respectively six weeks."( [The influence on nerve regeneration by the beta2-receptor agonist clenbuterol].
Fansa, H; Frerichs, O; Keilhoff, G; Schneider, W; Ziems, P, 2002
)
0.55
"The effect of repeated administration of clenbuterol in a growth-promoting dose on hepatocellular integrity of female pigs was assessed by correlating histopathologic lesions in the livers of dosed pigs with changes in serum ALT, AST, GGT and AP activities."( Effects of repeated growth-promoting doses of clenbuterol on the hepatic function of female pigs.
Gojmerac, T; Mirko, L; Pleadin, J; Stipica, C; Zuric, M, 2002
)
0.84
" It has been applied to the determination of (S)-(+)terbutaline and (R)-(-)-terbutaline in urine from healthy volunteer dosed with racemic terbutaline sulfate."( Determination of terbutaline enantiomers in human urine by capillary electrophoresis using hydroxypropyl-beta-cyclodextrin as a chiral selector.
Jeun, EY; Kang, JS; Kim, HJ; Kim, KH; Mar, W; Seo, SH; Youm, JR, 2003
)
0.32
"5 ml (a tenfold dosing error) of Ventipulmin syrup (72."( Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation.
Aaron, C; Daubert, GP; Leung, VW; Mabasa, VH, 2007
)
0.82
" The mRNA levels of StAR showed a significant decrease in the groups treated with CLB at the dosage of 18."( Effects of the β2 -agonist clenbuterol on testicular steroidogenic acute regulatory protein mRNA expression in adult rats.
Ma, JK; Zhu, WJ, 2010
)
0.66
" Using a rabbit model, we tested the dose-response pattern of the cardiovascular system to intravenous administration of clenbuterol."( Acute clenbuterol induces hypotension, atrioventricular block and cardiac asystole in the rabbit.
Cao, JM; Dong, R; Fu, LL; Guo, JF; Hong, XF; Ke, Y; Liu, Y; Xu, TM, 2013
)
1.08
"To describe plasma and urine concentrations of clenbuterol following administration of 2 commonly used dosing regimens to racing fit Thoroughbreds."( Detection, pharmacokinetics and cardiac effects following administration of clenbuterol to exercised horses.
Knych, HK; McKemie, DS; Mitchell, MM; Steinmetz, SJ, 2014
)
0.89
"Clenbuterol plasma concentrations were below the limit of quantification (10 pg/ml) of the assay by Day 4 in all horses receiving the chronic low-dose regimen and by Day 7 in 5 of 6 horses receiving the escalating dosing protocol."( Detection, pharmacokinetics and cardiac effects following administration of clenbuterol to exercised horses.
Knych, HK; McKemie, DS; Mitchell, MM; Steinmetz, SJ, 2014
)
2.07
" This study extends previous studies describing the pharmacokinetics of clenbuterol and describes plasma and urine concentrations following administration of 2 commonly used dosing regimens to racing fit Thoroughbreds, which will allow jurisdictions to establish withdrawal times in order to prevent inadvertent positive regulatory findings."( Detection, pharmacokinetics and cardiac effects following administration of clenbuterol to exercised horses.
Knych, HK; McKemie, DS; Mitchell, MM; Steinmetz, SJ, 2014
)
0.86
"The chiral inversion and pharmacokinetics of two enantiomers of trantinterol, a new β2 agonist, were studied in rats dosed (+)- or (-)-trantinterol separately."( Bidirectional chiral inversion of trantinterol enantiomers after separate doses to rats.
Cheng, M; Jing, L; Li, F; Pan, L; Qin, F; Sun, G; Wang, X, 2013
)
0.39
" For the application study, a total dosage of 30 µg clenbuterol was applied to 20 healthy volunteers on 5 subsequent days."( Statistical significance of hair analysis of clenbuterol to discriminate therapeutic use from contamination.
Anielski, P; Dvorak, J; Geyer, H; Gfrerer, L; Graw, M; Krumbholz, A; Schänzer, W; Thieme, D,
)
0.64
"To determine the anabolic and lipolytic effects of a low dosage of clenbuterol administered orally in working and nonworking equids."( Effect of long-term oral administration of a low dosage of clenbuterol on body fat percentage in working and nonworking adult horses.
Barr, CA; Boston, RC; Moore, CM; Nolen-Walston, RD; Soma, LR; Tomlinson, JE, 2015
)
0.9
" Nonworking horses received clenbuterol or placebo at the same dosage for 21 days in a crossover trial (2 treatments/horse)."( Effect of long-term oral administration of a low dosage of clenbuterol on body fat percentage in working and nonworking adult horses.
Barr, CA; Boston, RC; Moore, CM; Nolen-Walston, RD; Soma, LR; Tomlinson, JE, 2015
)
0.95
"2 μg/kg) for the escalating dosing regimen."( Differential expression of skeletal muscle genes following administration of clenbuterol to exercised horses.
Chouicha, N; Harrison, LM; Kass, PH; Knych, HK; Steinmetz, SJ, 2016
)
0.66
" The development of accurate analytical procedures to detect doping agents in sports is crucial in order to protect the fair-play of the game, avoid financial fraud in the attribution of eventual awards and, even more important, to protect the animals from harmful drugs and/or dangerous dosage regimens."( Quantification of doping compounds in faecal samples from racing pigeons, by liquid chromatography-tandem mass spectrometry.
André, MB; Bastos, ML; Carmo, H; de Pinho, PG; Moreira, FX; Ruivo, J; Ruivo, P; Silva, R, 2018
)
0.48
" The different dosing and mode of administration will lower the risk of side effects, increase the safety profile, and could facilitate use in the anti-obesity market."( Oxidized Hyaluronic Acid Hydrogels as a Carrier for Constant-Release Clenbuterol Against High-Fat Diet-Induced Obesity in Mice.
Chen, WY; Lin, FH, 2021
)
0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
bronchodilator agentAn agent that causes an increase in the expansion of a bronchus or bronchial tubes.
beta-adrenergic agonistAn agent that selectively binds to and activates beta-adrenergic receptors.
sympathomimetic agentA drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
ethanolamines
primary arylamineA primary amine formally derived from ammonia by replacing one hydrogen atom by an aryl group. R-NH2 where R is an aryl group.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
amino alcoholAn alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group.
substituted aniline
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency7.49780.006038.004119,952.5996AID1159521
regulator of G-protein signaling 4Homo sapiens (human)Potency0.11920.531815.435837.6858AID504845
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.00600.001530.607315,848.9004AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.03350.000229.305416,493.5996AID743080
cytochrome P450 2D6Homo sapiens (human)Potency34.67130.00108.379861.1304AID1645840
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.00210.001628.015177.1139AID1224843; AID1224895; AID1259393
DNA polymerase kappa isoform 1Homo sapiens (human)Potency16.83360.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency4.05330.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
Cellular tumor antigen p53Homo sapiens (human)Potency1.33330.002319.595674.0614AID651631
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency2.30470.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency2.37100.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.67050.00020.93267.2000AID395056; AID625205
Beta-2 adrenergic receptorHomo sapiens (human)Ki0.38930.00000.66359.5499AID1798855; AID395056; AID625205
Beta-1 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.12000.00021.46819.0000AID625204
Beta-1 adrenergic receptorHomo sapiens (human)Ki0.06900.00011.33919.9840AID625204
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)2.65200.00031.38338.4000AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki1.51500.00010.739610.0000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)2.65200.00051.48357.8000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki1.51500.00031.29679.2440AID625190
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)Kd0.01590.00000.62888.9130AID770362
Delta-type opioid receptorRattus norvegicus (Norway rat)EC50 (µMol)0.01300.00050.36496.9000AID395059
Beta-2 adrenergic receptor Bos taurus (cattle)Kd0.03600.00061.47759.1200AID40694
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)EC50 (µMol)0.01300.00020.88438.2000AID395059
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptor Bos taurus (cattle)Concentration1.00001.00005.500010.0000AID40688
Beta-2 adrenergic receptor Bos taurus (cattle)KD app0.03700.03701.17744.4800AID40687
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (178)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptor Bos taurus (cattle)
regulation of smooth muscle contractionBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of MAPK cascadeBeta-2 adrenergic receptor Bos taurus (cattle)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of autophagosome maturationBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of lipophagyBeta-2 adrenergic receptor Bos taurus (cattle)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (52)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptor Bos taurus (cattle)
protein homodimerization activityBeta-2 adrenergic receptor Bos taurus (cattle)
norepinephrine bindingBeta-2 adrenergic receptor Bos taurus (cattle)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptor Bos taurus (cattle)
Golgi apparatusBeta-2 adrenergic receptor Bos taurus (cattle)
receptor complexBeta-2 adrenergic receptor Bos taurus (cattle)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (78)

Assay IDTitleYearJournalArticle
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID395056Displacement of [3H]CGP1217 from human recombinant adrenergic beta2 receptor transfected in insect Sf9 cells by scintillation counting2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28725Partition coefficient of t-rotamer in octanol water system2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Determination of conformer-specific partition coefficients in octanol/water systems.
AID28724Partition coefficient of h-rotamer in octanol water system2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Determination of conformer-specific partition coefficients in octanol/water systems.
AID395059Agonist activity at adrenergic beta2 receptor in guinea pig trachea assessed as relaxation of carbachol-induced tissue contraction2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.
AID409957Inhibition of bovine liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID40687Apparent binding affinity constant to beta-2 adrenergic receptor determined using [3H]DHA1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID503306Antiproliferative activity against human PC3 cells at 2 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID24177log(1/ISA) value of the compound1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28893Partition coefficient (logP)2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Determination of conformer-specific partition coefficients in octanol/water systems.
AID40694Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID218845Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the membranes of bovine skeletal muscle preparation1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID40688Concentration required for maximal (95-100%) beta-2 adrenergic receptor occupancy1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID496772Modulation of neurological behavior in zebrafish assessed as effect on touch response by high-throughput screening2010Nature chemical biology, Mar, Volume: 6, Issue:3
Rapid behavior-based identification of neuroactive small molecules in the zebrafish.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID40686Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID235309Ratio of the dose raising the rat heart rate to 500bpm, to ED50 for inhibition of GDP binding to beta-3 adrenergic receptor1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID503294Agonist activity at beta-2-adrenergic receptor expressed in HEK293 cells assessed as induction of receptor interaction with beta-arrestin by EYFP based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID218847Change in Gibb's free energy at High affinity beta2- adrenoceptor in Chang living cells.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID218848Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID24440Calculated partition coefficient (clogP)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID41943Dose necessary to produce 50% of the isoprenaline effect to inhibit GDP binding to beta-3 adrenergic receptor in brown adipose tissue (BAT mitochondria) of rats after subcutaneous administration.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Selective beta 3-adrenergic agonists of brown adipose tissue and thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]acetates.
AID770362Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28723Partition coefficient of g-rotamer in octanol water system2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Determination of conformer-specific partition coefficients in octanol/water systems.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID40690Beta-2 adrenergic receptor intrinsic symphaticomimetic activity relative to salbutamol1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID409959Inhibition of bovine liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID770364Induction of Mitochondrial biogenesis in rabbit RPT cells at 10 to 3000 nM after 24 hrs by FCCP-OCR assay relative to control2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.
AID40695Intrinsic activity was measured as concentration of beta-2 adrenergic receptor agonist required for cAMP production1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1798855Beta-2 Adrenergic Receptor Binding Assay and Agonist Functionality Assay from Article 10.1021/jm801211c: \\Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.\\2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,435)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990269 (18.75)18.7374
1990's403 (28.08)18.2507
2000's362 (25.23)29.6817
2010's316 (22.02)24.3611
2020's85 (5.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials89 (5.91%)5.53%
Reviews38 (2.52%)6.00%
Case Studies48 (3.19%)4.05%
Observational0 (0.00%)0.25%
Other1,331 (88.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Detectability of Clenbuterol and Physiological Response in Human Skeletal Muscle [NCT03860870]16 participants (Anticipated)Interventional2019-03-11Recruiting
Targeting the Beta-2-adrenergic Pathway to Improve Skeletal Muscle Glucose Uptake in Obese Humans [NCT04921306]Phase 220 participants (Anticipated)Interventional2021-09-01Not yet recruiting
A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis [NCT04245709]Phase 225 participants (Actual)Interventional2020-02-10Completed
Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans: Myonuclear Addition, Hypertrophy and Myocellular Reprogramming [NCT05692856]60 participants (Anticipated)Interventional2023-02-01Recruiting
Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD) [NCT00585546]Phase 118 participants (Actual)Interventional2007-07-31Terminated(stopped due to No longer could obtain clenbuterol)
[NCT02557581]72 participants (Anticipated)Interventional2015-07-31Recruiting
A Placebo-controlled Study to Evaluate the Efficacy and Safety of Clenbuterol in Patients With Spinal and Bulbar Muscular Atrophy (SBMA) [NCT06169046]Phase 290 participants (Anticipated)Interventional2024-01-08Not yet recruiting
A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy [NCT01942590]Phase 1/Phase 217 participants (Actual)Interventional2013-09-30Completed
Targeting the Beta-2-adrenergic Pathway to Improve Skeletal Muscle Glucose Uptake in Healthy Humans [NCT03800290]Phase 211 participants (Actual)Interventional2019-06-01Completed
Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease Stably Treated With Enzyme Replacement Therapy [NCT04094948]Phase 20 participants (Actual)Interventional2023-01-01Withdrawn(stopped due to hasn't got the funding)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00585546 (10) [back to overview]Absolute Change in Left Ventricular Ejection Fraction From Explant to 18 Months Following Device Explant
NCT00585546 (10) [back to overview]Mean Change in Left Ventricular Ejection Fraction From Device Implant to Completion of Clenbuterol Therapy
NCT00585546 (10) [back to overview]Mean Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) From Baseline to 6 Months
NCT00585546 (10) [back to overview]Number of Subjects Who Received Maximum Target Dose of Clenbuterol
NCT00585546 (10) [back to overview]Percent of Subjects Who Experience LVAD Removal and Subsequent Freedom From Mechanical Circulatory Support or Heart Transplantation for 1-year After Explantation
NCT00585546 (10) [back to overview]The Number of Evaluable Subjects Meeting Explant Criteria and Subsequently Explanted
NCT00585546 (10) [back to overview]Time to Device Explant for Subjects Meeting Explant Criteria Defined in the Protocol
NCT00585546 (10) [back to overview]Absolute Percent Change in Serum Creatinine and Aspartate Transaminase (AST) From Baseline to Week 8 Post Clenbuterol
NCT00585546 (10) [back to overview]Absolute Percent Change in Serum Creatinine and Aspartate Transaminase (AST) From Baseline to Week 8 Post Implant
NCT00585546 (10) [back to overview]Mean Change in EuroQoL Visual Analog Scale (EQ5D-VAS) From Baseline to 6 Months and 1 Year Following Device Implant
NCT01942590 (13) [back to overview]Change in 6 Minute Walk Test
NCT01942590 (13) [back to overview]Change in 6 Minute Walk Test
NCT01942590 (13) [back to overview]Change in Forced Vital Capacity (FVC) in Pulmonary Function Testing
NCT01942590 (13) [back to overview]Change in Forced Vital Capacity (FVC) in Pulmonary Function Testing
NCT01942590 (13) [back to overview]Change in Urinary Glc4 Biomarker
NCT01942590 (13) [back to overview]Change in Urinary Glc4 Biomarker
NCT01942590 (13) [back to overview]Number of Participants With a Change in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Bilirubin Representing Liver Toxicity
NCT01942590 (13) [back to overview]Number of Participants With a Change in Creatine Kinase (CK) Reflecting Worsening of Muscle Involvement
NCT01942590 (13) [back to overview]GSGC (Gait, Stairs, Gowers, Arising From a Chair.)
NCT01942590 (13) [back to overview]Late-Life Function and Disability Instrument (LLFDI)
NCT01942590 (13) [back to overview]Maximum Expiratory Pressure (MEP)
NCT01942590 (13) [back to overview]Predicted Maximum Inspiration Pressure (MIP)
NCT01942590 (13) [back to overview]Quick Motor Function Test (QMFT)
NCT04245709 (3) [back to overview]Change in Motor Function Measured by ALSFRS-R
NCT04245709 (3) [back to overview]FVC Decline, Per-protocol Comparison
NCT04245709 (3) [back to overview]Number of Participants With Serious Adverse Events as Measured by Patient Reporting

Absolute Change in Left Ventricular Ejection Fraction From Explant to 18 Months Following Device Explant

(NCT00585546)
Timeframe: 18 months after explantation

Interventionabsolute change in ejection fraction (Number)
LVAD and Clenbuterol-.09

[back to top]

Mean Change in Left Ventricular Ejection Fraction From Device Implant to Completion of Clenbuterol Therapy

(NCT00585546)
Timeframe: up to 16 months, variable based on length of time receiveing clenbuterol

Interventionejection fraction (Mean)
LVAD and Clenbuterol0.16

[back to top]

Mean Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) From Baseline to 6 Months

Scale 0 - 105 (0- 5 on 21 items) where 0 means heart failure has not limited daily life at all and high scores mean that daily functions are greatly limited. (NCT00585546)
Timeframe: 6 months following LVAD implantation

Interventionunits on a scale (Mean)
LVAD and Clenbuterol28.3

[back to top]

Number of Subjects Who Received Maximum Target Dose of Clenbuterol

(NCT00585546)
Timeframe: Up to 16 months after LVAD implantation (12 months after beginning clenbuterol)

InterventionParticipants (Count of Participants)
LVAD and Clenbuterol13

[back to top]

Percent of Subjects Who Experience LVAD Removal and Subsequent Freedom From Mechanical Circulatory Support or Heart Transplantation for 1-year After Explantation

(NCT00585546)
Timeframe: One year after LVAD explant or until transplant or death (if not explanted)

Interventionpercentage of participants (Number)
LVAD and Clenbuterol5.6

[back to top]

The Number of Evaluable Subjects Meeting Explant Criteria and Subsequently Explanted

(NCT00585546)
Timeframe: Maximum 12 months after LVAD implantation

InterventionParticipants (Count of Participants)
LVAD and Clenbuterol1

[back to top]

Time to Device Explant for Subjects Meeting Explant Criteria Defined in the Protocol

Time from LVAD placement to explant for the single participant who achieved explant (NCT00585546)
Timeframe: Time to explant (but not to be followed for more than 16 months)

Interventionweeks (Number)
LVAD and Clenbuterol28

[back to top]

Absolute Percent Change in Serum Creatinine and Aspartate Transaminase (AST) From Baseline to Week 8 Post Clenbuterol

(NCT00585546)
Timeframe: baseline to week 8 post clenbuterol

Interventionpercent change (Mean)
creatinine from baseline to week 8 of clenbuterolAST from baseline to week 8 on clenbuterol
LVAD and Clenbuterol-15.815.6

[back to top]

Absolute Percent Change in Serum Creatinine and Aspartate Transaminase (AST) From Baseline to Week 8 Post Implant

(NCT00585546)
Timeframe: Up to 8 weeks after LVAD implantation

Interventionpercent change (Mean)
Creatinineaspartate transaminase (AST)
LVAD and Clenbuterol17.225

[back to top]

Mean Change in EuroQoL Visual Analog Scale (EQ5D-VAS) From Baseline to 6 Months and 1 Year Following Device Implant

Scale 0 - 100 where 0 is worst possible health state and 100 is perfect health. (NCT00585546)
Timeframe: 1 year following LVAD implantation

Interventionunits on a scale (Mean)
6 months post implant12 months post implant
LVAD and Clenbuterol4651

[back to top]

Change in 6 Minute Walk Test

Assess exercise tolerance in study patients; test administered by physical therapist. Subjects were asked to walk for 6 minutes, unassisted. The distance walked was recorded in meters. (NCT01942590)
Timeframe: Baseline, week 18

Interventionmeters (Mean)
Clenbuterol18.09
Placebo Comparator6.878

[back to top]

Change in 6 Minute Walk Test

Assess exercise tolerance in study patients; test administered by physical therapist. Subjects were asked to walk for 6 minutes, unassisted. The distance walked was recorded in meters. (NCT01942590)
Timeframe: Baseline, week 52

Interventionmeters (Mean)
Clenbuterol16.42
Placebo Comparator-18.13

[back to top]

Change in Forced Vital Capacity (FVC) in Pulmonary Function Testing

Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. (NCT01942590)
Timeframe: Baseline, Week 18

Interventionchange in FVC measured as % expected (Mean)
Clenbuterol1.575
Placebo Comparator2.825

[back to top]

Change in Forced Vital Capacity (FVC) in Pulmonary Function Testing

Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. (NCT01942590)
Timeframe: Baseline, Week 52

Interventionchange in FVC measured as % expected (Mean)
Clenbuterol-5.738
Placebo Comparator7.775

[back to top]

Change in Urinary Glc4 Biomarker

(NCT01942590)
Timeframe: Baseline, Week 52

Interventionmmol/mol CN (Mean)
Clenbuterol-1.1
Placebo Comparator-1.667

[back to top]

Change in Urinary Glc4 Biomarker

The Glc4 biomarker is measured in urine and correlates with muscle glycogen content. It is a noninvasive measurement that serves as a biomarker for Pompe disease. (NCT01942590)
Timeframe: Baseline, Week 18

Interventionmmol/mol CN (Mean)
Clenbuterol-1.733
Placebo Comparator0.0667

[back to top]

Number of Participants With a Change in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Bilirubin Representing Liver Toxicity

Liver toxicity, as defined by a >3x increase in AST or ALT from the respective baseline values and/or an increase in direct, indirect or total bilirubin of >3x the upper limit of normal (NCT01942590)
Timeframe: Any point up to week 52

Interventionparticipants (Number)
Clenbuterol0
Placebo Comparator0

[back to top]

Number of Participants With a Change in Creatine Kinase (CK) Reflecting Worsening of Muscle Involvement

Worsening muscle involvement, as defined by >3x increase in CK from baseline that is >2x the upper limit of normal (NCT01942590)
Timeframe: Any point up to week 52

Interventionparticipants (Number)
Clenbuterol1
Placebo Comparator0

[back to top]

GSGC (Gait, Stairs, Gowers, Arising From a Chair.)

The GSGC is a criterion referenced assessment designed to measure functional status and change in gross motor function over time and, in particular, to measure clinically relevant change. Consists of 4 components: Gait, Climbing Stairs, Gower's Manuever, Arising From a Chair. Lowest score 4 = normal muscle function, highest score 27 = unable to perform motor function tests. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52

,
Interventionunits on a scale (Mean)
BaselineWeek 18Week 52
Clenbuterol1715.1413.8
Placebo Comparator7.56.56.5

[back to top]

Late-Life Function and Disability Instrument (LLFDI)

The Late-Life Function & Disability Instrument (Late-Life FDI) is an evaluative outcome instrument for community-dwelling older adults. Highest score 240 = normal function and no disability, lowest score 0 = low levels of frequency of participating in life tasks. (NCT01942590)
Timeframe: Baseline, Week 18, Week 52

Interventionunits on a scale (Mean)
BaselineWeek 18Week 52
Clenbuterol103.75106.7112.5

[back to top]

Maximum Expiratory Pressure (MEP)

MEP reflects the strength of the abdominal muscles and other expiratory muscles. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52

,
Interventionpercentage of MEP (Mean)
BaselineWeek 18Week 52
Clenbuterol40.44053.9
Placebo Comparator62.883.349.2

[back to top]

Predicted Maximum Inspiration Pressure (MIP)

MIP is a measurement of inspiratory muscle weakness, including weakness of the diaphragm. MIP is decreased in Pompe disease and reflects weakness of respiratory muscles. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52

,
Interventionpercentage of MIP (Mean)
BaselineWeek 18Week 52
Clenbuterol56.347.468.5
Placebo Comparator96.883.8104.6

[back to top]

Quick Motor Function Test (QMFT)

The QMFT is a criterion referenced assessment designed to measure functional status and change in gross motor function over time and, in particular, to measure clinically relevant change. Consists of 16 motor function tests. Lowest score 0 = unable to perform motor function tests, highest score 64 = normal muscle function. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52

,
Interventionunits on a scale (Mean)
BaselineWeek 18Week 52
Clenbuterol3540.646.5
Placebo Comparator53.7554.7556.25

[back to top]

Change in Motor Function Measured by ALSFRS-R

The ALS Functional Rating Scale (ALSFRS-R) - 12 questions rated on a five-point scale, where 0= can't do, to 5= normal ability. It is utilized for monitoring the progression of disability in patients with ALS. The critical test for efficacy was comparison of the mean slope of the ALSFRS-R during treatment compared to pre-treatment. Pre-treatment slope for each participant was estimated as follows: (48-enrollment ALSFRS-R)/months since symptom onset. A statistically significant treatment effect was determined by a two-tailed, t-test, with a critical p value < .05. Other analyses included a repeated measures ANOVA design (between and within subjects) of ALSFRS-R slopes before and during treatment. (NCT04245709)
Timeframe: Baseline, week 4, week 12, week 16, week 20, and week 24

Interventionslope (Mean)
Open Label Arm-0.17

[back to top]

FVC Decline, Per-protocol Comparison

Comparison of the mean slope of percent predicted FVC during treatment versus pre-treatment. Pre-treatment slope for each participant was estimated as follows: (100%-enrollment percent predicted FVC)/months since symptom onset. (NCT04245709)
Timeframe: Baseline, week 4, week 12, and week 24

Interventionslope (Mean)
Open Label Arm-0.25

[back to top]

Number of Participants With Serious Adverse Events as Measured by Patient Reporting

The primary endpoint is safety of clenbuterol at 80 mcg BID. Adverse events and serious adverse events will be systematically gathered as the dose is increased. (NCT04245709)
Timeframe: Up to 24 weeks

InterventionParticipants (Count of Participants)
Open Label Arm2

[back to top]